Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms

Rashmi Kanagal-Shamanna, Jennelle C. Hodge, Tracy Tucker, Shashi Shetty, Ashwini Yenamandra, Amanda Dixon-McIver, Christine Bryke, Emma Huxley, Patrick A. Lennon, Gordana Raca, Xinjie Xu, Sally Jeffries, Fabiola Quintero-Rivera, Patricia T. Greipp, Marilyn L. Slovak, M. Anwar Iqbal, Min Fang

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Fingerprint

Dive into the research topics of 'Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms'. Together they form a unique fingerprint.

Medicine & Life Sciences